Neurodegenerative Diseases

Newest Neurodegenerative Diseases Information

6 Best Peptides for ALS (Amyotrophic Lateral Sclerosis)

Six peptides come up most consistently when people research options for ALS, ranging from Cerebrolysin, a neurotrophic mixture with real European clinical use, to preclinical-only candidates like Colivelin and P21 that are followed closely in research-oriented patient communities. No peptide has been proven in human trials to slow or reverse ALS progression, and the honest state of the evidence for each compound below ranges from extrapolated animal data to limited real-world use. The entries are ordered by how prominently each appears in research and documented real-world use for ALS, not as a recommendation of one over another, and none of them are substitutes for specialist care.

Neurodegenerative Diseases 11 min read

5 Best Peptides for Huntington's Disease

Huntington's Disease occupies an unusual place in peptide research: several compounds have emerged as candidates through preclinical science and mechanistic reasoning, but none has completed human clinical trials, and the broader peptide community has not widely adopted HD as a routine protocol target the way it has for conditions like cognitive decline or joint repair. This guide covers the five peptides that researchers and informed observers are actually discussing for HD, from HD-specific experimental compounds like P42 to neuroprotective options like Cerebrolysin and Semax whose mechanisms overlap meaningfully with HD pathology. They are ordered by how prominently each appears in the research and in informed HD discussion, not ranked as recommendations, and the evidence across all five is honestly thin, preclinical for the HD-specific entries and entirely extrapolated for the neuroprotective ones.

Neurodegenerative Diseases 9 min read

7 Best Peptides for Chronic Traumatic Encephalopathy (CTE)

Seven peptides are actively used or discussed for Chronic Traumatic Encephalopathy (CTE) in 2026, ranging from CN-105, the most clinically advanced pipeline candidate, to community-explored compounds like BPC-157 and Selank. No peptide has been approved or proven to treat CTE, and the human evidence base is thin across the board because CTE cannot currently be confirmed in a living person, making clinical trial design exceptionally difficult. The compounds in this guide are numbered by how prominently each appears in the research literature and in documented real-world use, not ranked as recommendations from one to the next, and the MyPeptidePal app is built to help turn that landscape into a personalized plan.

Neurodegenerative Diseases 11 min read

6 Best Peptides for Frontotemporal Dementia

Frontotemporal dementia sits at one of the hardest edges of the peptide research landscape. No peptide is approved for FTD, and the human evidence base is thinner here than for almost any other condition in this library. What exists is a small set of compounds that researchers and a narrow circle of practitioners have explored in the context of FTD's underlying biology, from neurotrophic mixtures with clinical records in other dementias to experimental molecules studied only in animal models. This guide covers six of them honestly, numbered by how prominently each appears in research and documented use relevant to FTD, not ranked as a recommendation of one over another. For most people navigating this condition, the question of which compound to explore is best worked through with a qualified clinician and the personalized tools in the MyPeptidePal app.

Neurodegenerative Diseases 10 min read

6 Best Peptides for Dementia

Six peptides come up consistently when people research cognitive support for dementia: Cerebrolysin, Semax, Cortexin, Dihexa, Pinealon, and P21. They range from compounds with genuine human trial data used clinically in parts of Europe and Asia to research chemicals whose evidence base is entirely animal models or community-reported experience. None is FDA-approved for dementia, and none replaces evaluated medical care. This guide covers each one in plain language, what it is, how people use it for dementia, and what the evidence actually shows. The compounds are numbered by how prominently each appears in research and real-world use, not ranked as personal recommendations, and turning any of these options into a personalized plan is exactly what the MyPeptidePal app is built to do.

Neurodegenerative Diseases 10 min read

dont Spend six hours researching every peptide.

About MyPeptidePal

MyPeptidePal is the world's largest peptide knowledge base and your personal AI peptide expert in one. Trained on every published study and over 10,000 protocols, it gets smarter every day, learning from new research and a community actively running and tracking their own. Build a personalized protocol in 60 seconds, get dosing math you can trust, find vetted suppliers, set auto-pilot reminders, and get straight answers on peptides, health, fitness, and longevity, all in one place. Try for FREE Here, no credit card required.